Blog & Article
- 12th June 2025
Journal Articles related to Clinical Development Services
Journal Article
This article explores how Bayesian statistics make it possible to take observations made during the validation of the analytical procedure and predict the uncertainty around any future result, and in doing so, bridge the gaps that exist in the guidelines.
Journal Article
With both the cost and time to bring a drug to market ballooning, the importance of an integrated product development (IPD) strategy is gaining traction. This multidisciplinary approach to drug development brings key stakeholders together, breaking down barriers to an e!cient and cost-e”ective path to market. But while more organisations are adopting an IPD strategy, a recent industry survey found most aren’t doing so early enough. Frédéric Pailloux, Senior Director, Head of Integrated Product Development and Consulting at PharmaLex examines the IPD journey.
Journal Article
After nearly six months of war, life for patients in Ukraine continues to get harder. The World Health Organization (WHO) has reported that people’s health has been imperiled by difficulty in accessing emergency care and essential medicines. Dr. Hans Henri P. Kluge, WHO Regional Director for Europe, noted that there had been more than 260 verified attacks on healthcare in Ukraine by early June, resulting in some health facilities being destroyed and others struggling to cope with people seeking care from trauma and injuries.
Journal Article
Biopharma companies are grasping the key role an integrated product development strategy can play in the drug development process. A recent industry survey found growing uptake of this multidisciplinary approach to improving efficiency and reducing costs and timelines, though the barriers to successful implementation were similar across the board.
Journal Article
International Pharmaceutical Industry: Marta Vila Ramos discusses the impact of COVID-19 on the industry and what we can expect in the future.
Journal Article
Over the past 12 months, the bio/pharma industry has faced unprecedented challenges head on, working in unique and remote ways, and forming new and unlikely partnerships to help in the fight against the COVID-19 pandemic. Although a hugely impactful aspect of 2020, COVID-19 has not been the only trial of the year; bio/pharma companies have also had to keep a watchful eye on Brexit—the departure of the United Kingdom from the European Union—which is expected to cause broad-level disruptions to companies throughout the region.
Journal Article
International Pharmaceutical Industry: Sebastian Joseph discusses regulatory expectations for the non-clinical development of vaccines
Journal Article
Zeb Younes & Zaklina Buljovcic will give you insightful information about new approaches to Drug Development. This article is taken from the European Biopharmaceutical Review October 2019, pages 58-64. © Samedan Ltd.